vs
Side-by-side financial comparison of Great Lakes Dredge & Dock CORP (GLDD) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Great Lakes Dredge & Dock CORP is the larger business by last-quarter revenue ($256.5M vs $129.7M, roughly 2.0× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 26.5%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 13.6%).
Great Lakes Dredge and Dock Company is an American company providing construction services in dredging and land reclamation, currently the largest such provider in the United States. GLD&D operates primarily in the United States but conducts one-quarter of its business overseas. The company was based in Oak Brook, Illinois, but in October 2020 relocated its corporate headquarters to Houston, Texas.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
GLDD vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $256.5M | $129.7M |
| Net Profit | $12.6M | — |
| Gross Margin | 20.9% | 98.0% |
| Operating Margin | 12.7% | -25.0% |
| Net Margin | 4.9% | — |
| Revenue YoY | 26.5% | 73.4% |
| Net Profit YoY | -35.9% | — |
| EPS (diluted) | $0.19 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $256.5M | $129.7M | ||
| Q3 25 | $195.2M | $164.9M | ||
| Q2 25 | $193.8M | $114.4M | ||
| Q1 25 | $242.9M | $81.7M | ||
| Q4 24 | $202.8M | $74.8M | ||
| Q3 24 | $191.2M | $62.9M | ||
| Q2 24 | $170.1M | $54.1M | ||
| Q1 24 | $198.7M | $41.4M |
| Q4 25 | $12.6M | — | ||
| Q3 25 | $17.7M | $25.7M | ||
| Q2 25 | $9.7M | $-12.8M | ||
| Q1 25 | $33.4M | $-41.2M | ||
| Q4 24 | $19.7M | — | ||
| Q3 24 | $8.9M | $-54.8M | ||
| Q2 24 | $7.7M | $-70.4M | ||
| Q1 24 | $21.0M | $-136.1M |
| Q4 25 | 20.9% | 98.0% | ||
| Q3 25 | 22.4% | 99.0% | ||
| Q2 25 | 18.9% | 98.7% | ||
| Q1 25 | 28.6% | 94.3% | ||
| Q4 24 | 24.1% | 96.6% | ||
| Q3 24 | 19.0% | 97.4% | ||
| Q2 24 | 17.5% | 96.2% | ||
| Q1 24 | 22.9% | 96.4% |
| Q4 25 | 12.7% | -25.0% | ||
| Q3 25 | 14.4% | 15.1% | ||
| Q2 25 | 8.8% | -11.1% | ||
| Q1 25 | 20.6% | -52.2% | ||
| Q4 24 | 14.8% | -81.2% | ||
| Q3 24 | 8.7% | -89.3% | ||
| Q2 24 | 8.6% | -125.1% | ||
| Q1 24 | 15.8% | -336.5% |
| Q4 25 | 4.9% | — | ||
| Q3 25 | 9.1% | 15.6% | ||
| Q2 25 | 5.0% | -11.1% | ||
| Q1 25 | 13.8% | -50.4% | ||
| Q4 24 | 9.7% | — | ||
| Q3 24 | 4.6% | -87.1% | ||
| Q2 24 | 4.5% | -130.1% | ||
| Q1 24 | 10.6% | -328.9% |
| Q4 25 | $0.19 | $0.04 | ||
| Q3 25 | $0.26 | $0.28 | ||
| Q2 25 | $0.14 | $-0.14 | ||
| Q1 25 | $0.49 | $-0.47 | ||
| Q4 24 | $0.29 | $-0.71 | ||
| Q3 24 | $0.13 | $-0.70 | ||
| Q2 24 | $0.11 | $-0.91 | ||
| Q1 24 | $0.31 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.4M | $93.0M |
| Total DebtLower is stronger | $378.2M | — |
| Stockholders' EquityBook value | $517.1M | $114.8M |
| Total Assets | $1.3B | $605.2M |
| Debt / EquityLower = less leverage | 0.73× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.4M | $93.0M | ||
| Q3 25 | $12.7M | $110.9M | ||
| Q2 25 | $2.9M | $75.2M | ||
| Q1 25 | $11.3M | $61.9M | ||
| Q4 24 | $10.2M | $58.5M | ||
| Q3 24 | $12.0M | $36.4M | ||
| Q2 24 | $23.1M | $32.3M | ||
| Q1 24 | $22.8M | $43.3M |
| Q4 25 | $378.2M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $448.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $517.1M | $114.8M | ||
| Q3 25 | $502.1M | $73.6M | ||
| Q2 25 | $481.9M | $32.7M | ||
| Q1 25 | $479.9M | $32.8M | ||
| Q4 24 | $448.9M | $59.1M | ||
| Q3 24 | $425.4M | $-30.5M | ||
| Q2 24 | $418.0M | $15.1M | ||
| Q1 24 | $409.0M | $74.1M |
| Q4 25 | $1.3B | $605.2M | ||
| Q3 25 | $1.3B | $538.6M | ||
| Q2 25 | $1.2B | $555.3M | ||
| Q1 25 | $1.2B | $548.8M | ||
| Q4 24 | $1.3B | $594.1M | ||
| Q3 24 | $1.1B | $504.4M | ||
| Q2 24 | $1.1B | $551.1M | ||
| Q1 24 | $1.1B | $663.5M |
| Q4 25 | 0.73× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $79.7M | $60.7M |
| Free Cash FlowOCF − Capex | $50.3M | — |
| FCF MarginFCF / Revenue | 19.6% | — |
| Capex IntensityCapex / Revenue | 11.5% | — |
| Cash ConversionOCF / Net Profit | 6.31× | — |
| TTM Free Cash FlowTrailing 4 quarters | $99.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $79.7M | $60.7M | ||
| Q3 25 | $49.2M | $14.3M | ||
| Q2 25 | $56.9M | $5.0M | ||
| Q1 25 | $60.9M | $-42.2M | ||
| Q4 24 | $-13.5M | $-35.7M | ||
| Q3 24 | $26.8M | $-42.5M | ||
| Q2 24 | $18.4M | $-40.2M | ||
| Q1 24 | $38.4M | $-119.0M |
| Q4 25 | $50.3M | — | ||
| Q3 25 | $13.2M | $14.2M | ||
| Q2 25 | $-3.7M | — | ||
| Q1 25 | $39.6M | — | ||
| Q4 24 | $-36.1M | — | ||
| Q3 24 | $-11.5M | — | ||
| Q2 24 | $-34.0M | $-40.3M | ||
| Q1 24 | $26.5M | — |
| Q4 25 | 19.6% | — | ||
| Q3 25 | 6.8% | 8.6% | ||
| Q2 25 | -1.9% | — | ||
| Q1 25 | 16.3% | — | ||
| Q4 24 | -17.8% | — | ||
| Q3 24 | -6.0% | — | ||
| Q2 24 | -20.0% | -74.5% | ||
| Q1 24 | 13.4% | — |
| Q4 25 | 11.5% | — | ||
| Q3 25 | 18.4% | 0.1% | ||
| Q2 25 | 31.3% | — | ||
| Q1 25 | 8.7% | — | ||
| Q4 24 | 11.2% | — | ||
| Q3 24 | 20.0% | 0.0% | ||
| Q2 24 | 30.8% | 0.2% | ||
| Q1 24 | 6.0% | 0.0% |
| Q4 25 | 6.31× | — | ||
| Q3 25 | 2.77× | 0.56× | ||
| Q2 25 | 5.87× | — | ||
| Q1 25 | 1.82× | — | ||
| Q4 24 | -0.69× | — | ||
| Q3 24 | 3.02× | — | ||
| Q2 24 | 2.39× | — | ||
| Q1 24 | 1.83× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GLDD
Segment breakdown not available.
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
